This company has been marked as potentially delisted and may not be actively trading. NASDAQ:AXDX Accelerate Diagnostics (AXDX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestSustainabilityTrendsBuy This Stock About Accelerate Diagnostics Stock (NASDAQ:AXDX) 30 days 90 days 365 days Advanced Chart Get Accelerate Diagnostics alerts:Sign Up Key Stats Today's Range N/A50-Day Range$0.03▼$1.1852-Week Range N/AVolume53.64 million shsAverage Volume562,314 shsMarket Capitalization$857 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingStrong Buy Company Overview Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was incorporated in 1982 and is headquartered in Tucson, Arizona. Read More Accelerate Diagnostics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks16th Percentile Overall ScoreAXDX MarketRank™: Accelerate Diagnostics scored higher than 16% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Accelerate Diagnostics.Read more about Accelerate Diagnostics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Accelerate Diagnostics are expected to grow in the coming year, from ($2.30) to ($2.00) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Accelerate Diagnostics is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Accelerate Diagnostics is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for AXDX. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAccelerate Diagnostics does not currently pay a dividend.Dividend GrowthAccelerate Diagnostics does not have a long track record of dividend growth. Sustainability and ESG4.7 / 5Environmental Score-1.62 Short InterestThere is no current short interest data available for AXDX. News and Social Media0.6 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Accelerate Diagnostics this week, compared to 0 articles on an average week. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Accelerate Diagnostics insiders have not sold or bought any company stock.Percentage Held by Insiders43.60% of the stock of Accelerate Diagnostics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 17.14% of the stock of Accelerate Diagnostics is held by institutions.Read more about Accelerate Diagnostics' insider trading history. Receive AXDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Accelerate Diagnostics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AXDX Stock News HeadlinesAccelerate Awards Grants to Boost Student Outcomes with Evidence-Based Tutoring and Technology in Classrooms NationwideAugust 27 at 3:49 PM | finance.yahoo.comAccelerate Diagnostics Delays Q2 2025 ReportAugust 18, 2025 | tipranks.comMissed the Last 10,000% Surge? Here’s Your Next ChanceAxcelis Technologies went from $2.50 to $180—a staggering 7,100% return. These are the kinds of small-cap breakouts Fierce Analyst aims to catch before they go mainstream. Our research team uses data and trend analysis to uncover high-potential stocks early. And now, you can get free alerts on the next set of breakout candidates—before the crowd rushes in.August 29 at 2:00 AM | Fierce Investor (Ad)Accelerate Diagnostics Liquidation Plan Confirmed by CourtAugust 18, 2025 | tipranks.comAccelerate Diagnostics Files for Chapter 11 BankruptcyJune 4, 2025 | tipranks.comFirm Retention Summary: Accelerate DiagnosticsMay 23, 2025 | wsj.comAccelerate Diagnostics Delays 10-Q Filing Amid BankruptcyMay 16, 2025 | tipranks.comAccelerate Diagnostics Initiates Chapter 11 Restructuring ProceedingMay 10, 2025 | nasdaq.comSee More Headlines AXDX Stock Analysis - Frequently Asked Questions How were Accelerate Diagnostics' earnings last quarter? Accelerate Diagnostics, Inc. (NASDAQ:AXDX) announced its quarterly earnings results on Thursday, March, 20th. The medical research company reported ($0.37) earnings per share for the quarter, topping analysts' consensus estimates of ($0.50) by $0.13. The medical research company had revenue of $2.82 million for the quarter, compared to analyst estimates of $3 million. When did Accelerate Diagnostics' stock split? Accelerate Diagnostics shares reverse split on the morning of Wednesday, July 12th 2023.The 1-10 reverse split was announced on Wednesday, July 12th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, July 12th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of Accelerate Diagnostics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Accelerate Diagnostics investors own include Himax Technologies (HIMX), Sangamo Therapeutics (SGMO), Magnachip Semiconductor (MX), Universal Display (OLED), Energy Transfer (ET), Fluidigm (FLDM) and Netflix (NFLX). Company Calendar Last Earnings3/20/2025Today8/29/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Analytical instruments Sub-IndustryMeasuring And Control Equipment Current SymbolNASDAQ:AXDX CIK727207 Webacceleratediagnostics.com Phone(520) 365-3100Fax520-269-6580Employees220Year FoundedN/AProfitability EPS (Trailing Twelve Months)($2.34) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$61.62 million Net Margins-471.83% Pretax Margin-444.14% Return on EquityN/A Return on Assets-191.66% Debt Debt-to-Equity RatioN/A Current Ratio1.50 Quick Ratio1.34 Sales & Book Value Annual Sales$11.70 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value($1.37) per share Price / BookN/AMiscellaneous Outstanding Shares25,210,000Free Float14,125,000Market Cap$857 thousand OptionableOptionable Beta0.22 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:AXDX) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Accelerate Diagnostics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Accelerate Diagnostics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.